Cargando…

The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus

BACKGROUND: Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma gly...

Descripción completa

Detalles Bibliográficos
Autores principales: Puig-Jové, Carlos, Julve, Josep, Castelblanco, Esmeralda, Julián, M Teresa, Amigó, Núria, Andersen, Henrik U, Ahluwalia, Tarunveer S, Rossing, Peter, Mauricio, Dídac, Jensen, Magnus T, Alonso, Núria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700974/
https://www.ncbi.nlm.nih.gov/pubmed/36434633
http://dx.doi.org/10.1186/s12933-022-01652-z
_version_ 1784839436475826176
author Puig-Jové, Carlos
Julve, Josep
Castelblanco, Esmeralda
Julián, M Teresa
Amigó, Núria
Andersen, Henrik U
Ahluwalia, Tarunveer S
Rossing, Peter
Mauricio, Dídac
Jensen, Magnus T
Alonso, Núria
author_facet Puig-Jové, Carlos
Julve, Josep
Castelblanco, Esmeralda
Julián, M Teresa
Amigó, Núria
Andersen, Henrik U
Ahluwalia, Tarunveer S
Rossing, Peter
Mauricio, Dídac
Jensen, Magnus T
Alonso, Núria
author_sort Puig-Jové, Carlos
collection PubMed
description BACKGROUND: Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM. METHODS: We included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e′≥12 or E/e′ 8–12 + volume of the left atrium > 34 ml/m2. To identify a metabolic profile associated with the presence of subclinical myocardial dysfunction, a multivariate supervised model of classification based on least squares regression (PLS-DA regression) was performed. RESULTS: One-hundred forty-six subjects had diastolic dysfunction and 18 systolic dysfunction. Compared to the control group, patients with myocardial dysfunction had longer duration of diabetes (p = 0.005), and higher BMI (p = 0.013), serum NTproBNP concentration (p = 0.001), systolic blood pressure (p < 0.001), albuminuria (p < 0.001), and incidence of advanced retinopathy (p < 0.001). The supervised classification model identified a specific pattern associated with myocardial dysfunction, with a capacity to discriminate patients with myocardial dysfunction from controls. PLS-DA showed that triglyceride-rich lipoproteins (TGRLs), such as VLDL (total VLDL particles, large VLDL subclass and VLDL-TG content) and IDL (IDL cholesterol content), as well as the plasma concentration of GlycA, were associated with the presence of subclinical myocardial dysfunction. CONCLUSION: Proatherogenic TGRLs and the proinflammatory biomarker Glyc A are strongly associated to myocardial dysfunction in T1DM. These findings suggest a pivotal role of TGRLs and systemic inflammation in the development of subclinical myocardial dysfunction in T1DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01652-z.
format Online
Article
Text
id pubmed-9700974
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97009742022-11-27 The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus Puig-Jové, Carlos Julve, Josep Castelblanco, Esmeralda Julián, M Teresa Amigó, Núria Andersen, Henrik U Ahluwalia, Tarunveer S Rossing, Peter Mauricio, Dídac Jensen, Magnus T Alonso, Núria Cardiovasc Diabetol Research BACKGROUND: Subjects with Type 1 diabetes mellitus (T1DM) have an increased incidence of heart failure (HF). Several pathophysiological mechanisms have been involved in its development. The aim of this study was to analyze the potential contribution of the advanced lipoprotein profile and plasma glycosylation (GlycA) to the presence of subclinical myocardial dysfunction in subjects with T1DM. METHODS: We included subjects from a Danish cohort of T1DM subjects (Thousand & 1 study) with either diastolic and/or systolic subclinical myocardial dysfunction, and a control group without myocardial dysfunction, matched by age, sex and HbA1c. All underwent a transthoracic echocardiogram and an advanced lipoprotein profile obtained by using the NMR-based Liposcale® test. GlycA NMR signal was also analyzed. Systolic dysfunction was defined as left ventricular ejection fraction ≤ 45% and diastolic dysfunction was considered as E/e′≥12 or E/e′ 8–12 + volume of the left atrium > 34 ml/m2. To identify a metabolic profile associated with the presence of subclinical myocardial dysfunction, a multivariate supervised model of classification based on least squares regression (PLS-DA regression) was performed. RESULTS: One-hundred forty-six subjects had diastolic dysfunction and 18 systolic dysfunction. Compared to the control group, patients with myocardial dysfunction had longer duration of diabetes (p = 0.005), and higher BMI (p = 0.013), serum NTproBNP concentration (p = 0.001), systolic blood pressure (p < 0.001), albuminuria (p < 0.001), and incidence of advanced retinopathy (p < 0.001). The supervised classification model identified a specific pattern associated with myocardial dysfunction, with a capacity to discriminate patients with myocardial dysfunction from controls. PLS-DA showed that triglyceride-rich lipoproteins (TGRLs), such as VLDL (total VLDL particles, large VLDL subclass and VLDL-TG content) and IDL (IDL cholesterol content), as well as the plasma concentration of GlycA, were associated with the presence of subclinical myocardial dysfunction. CONCLUSION: Proatherogenic TGRLs and the proinflammatory biomarker Glyc A are strongly associated to myocardial dysfunction in T1DM. These findings suggest a pivotal role of TGRLs and systemic inflammation in the development of subclinical myocardial dysfunction in T1DM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-022-01652-z. BioMed Central 2022-11-24 /pmc/articles/PMC9700974/ /pubmed/36434633 http://dx.doi.org/10.1186/s12933-022-01652-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Puig-Jové, Carlos
Julve, Josep
Castelblanco, Esmeralda
Julián, M Teresa
Amigó, Núria
Andersen, Henrik U
Ahluwalia, Tarunveer S
Rossing, Peter
Mauricio, Dídac
Jensen, Magnus T
Alonso, Núria
The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
title The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
title_full The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
title_fullStr The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
title_full_unstemmed The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
title_short The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
title_sort novel inflammatory biomarker glyca and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700974/
https://www.ncbi.nlm.nih.gov/pubmed/36434633
http://dx.doi.org/10.1186/s12933-022-01652-z
work_keys_str_mv AT puigjovecarlos thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT julvejosep thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT castelblancoesmeralda thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT julianmteresa thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT amigonuria thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT andersenhenriku thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT ahluwaliatarunveers thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT rossingpeter thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT mauriciodidac thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT jensenmagnust thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT alonsonuria thenovelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT puigjovecarlos novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT julvejosep novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT castelblancoesmeralda novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT julianmteresa novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT amigonuria novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT andersenhenriku novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT ahluwaliatarunveers novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT rossingpeter novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT mauriciodidac novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT jensenmagnust novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus
AT alonsonuria novelinflammatorybiomarkerglycaandtriglyceriderichlipoproteinsareassociatedwiththepresenceofsubclinicalmyocardialdysfunctioninsubjectswithtype1diabetesmellitus